These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23409693)

  • 1. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus.
    Karaiskos D; Tzavellas E; Ilias I; Liappas I; Paparrigopoulos T
    Int J Clin Pract; 2013 Mar; 67(3):257-60. PubMed ID: 23409693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - the Croatian study.
    Filipcić I; Margetić B; Simunović I; Jakovljević M
    Psychiatr Danub; 2010 Jun; 22(2):231-5. PubMed ID: 20562752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of agomelatine in previously-treated depressed patients.
    Kasper S; Hajak G
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine: an antidepressant without deterioration of sexual response.
    Sapetti A
    J Sex Marital Ther; 2012; 38(2):190-7. PubMed ID: 22390531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial.
    Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J
    Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA; Bosker FJ; Meesters Y
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sertraline effectiveness and safety in depressed oncological patients.
    Torta R; Siri I; Caldera P
    Support Care Cancer; 2008 Jan; 16(1):83-91. PubMed ID: 17874143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients.
    Rachdi C; Damak R; Fekih Romdhane F; Ouertani H; Cheour M
    Prim Care Diabetes; 2019 Feb; 13(1):57-62. PubMed ID: 30287230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
    Ferguson JM; Shrivastava RK; Stahl SM; Hartford JT; Borian F; Ieni J; McQuade RD; Jody D
    J Clin Psychiatry; 2001 Jan; 62(1):24-9. PubMed ID: 11235924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, baseline controlled evaluation of sertraline safety and efficacy in the treatment of depression in Thai patients.
    SESS Group (Sertraline Efficacy and Safety Study Group)
    J Med Assoc Thai; 2001 Jan; 84(1):54-62. PubMed ID: 11281500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
    Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.